IRMI

Multi-regional infrastructure for the development of advanced treatment aimed at organ and tissue regeneration. 

An effective co-operation system was set up to direct different skills and technologies into a single entity – Infrastruttura Italiana di Medicina Rigenerativa (Italian Regenerative Medicine Infrastructure) – in order to rapidly optimize new treatment strategies for chronic diseases by repairing, replacing or regenerating organs and tissues damaged by disease or aging.

The IRMI Project will favour transfer of research studies performed by major Italian universities into products approved for human use; it will make it possible to treat expensive chronic diseases at considerably lower costs for the national health system and introduce new, more effective and cheaper treatments into clinical practice.

This infrastructure has been set up to start an entirely Italian specialization process in regenerative medicine at a European and international level by enhancing biobanking and cellular manipulation infrastructures.

At the end of the research and development process, at least six new innovative products are expected to be placed on the market and at least two advanced treatment cellular products based on epithelial stem cell cultures are expected to move to phase 2 of testing. This infrastructure will ensure training of new professional figures in the various segments of regenerative medicine and create over 100 new jobs internally.

Project Leader: Maria Pia Hospital

Partners: AB Tremila, Genomnia, Igea, Manatee, AB Medica Spa, Chiesi Farmaceutici, Ismet, Villa Maria Hospital, Istituto Ortopedico Rizzoli, Università degli Studi di Milano, Università di Bologna, Università di Modena e Reggio Emilia, Politecnico di Torino, CNR

Project Manager: Pier Maria Fornasari (Istituto Ortopedico Rizzoli)

Accounting Manager: Carlo Di Giambattista (Gruppo Villa Maria)

Training Manager: Prof. Lorenzo Silengo (Università di Torino)